253315-22-9

Basic information

• Product Name: 6-(1H-Pyrazol-1-yl)nicotinic acid
• Synonyms: 6-Pyrazol-1-yl-nicotinic acid;6-(1H-Pyrazol-1-yl)nicotinic acid ,97%;6-(1H-Pyrazol-1-yl)pyridine-3-carboxylic acid;6-(1H-Pyrazol-1-yl)nicotinic acid;6-pyrazol-1-ylpyridine-3-carboxylic acid
• CAS NO: 253315-22-9
• Molecular Formula: C₉H₇N₃O₂
• Molecular Weight: 189.17
• Mol File: 253315-22-9.mol

Chemical Properties

• Melting Point: 272-274℃
• Boiling Point: 394.6 °C at 760 mmHg
• Flash Point: 192.5 °C
• Appearance: /
• Density: 1.39 g/cm³
• Vapor Pressure: 6.19E-07mmHg at 25°C
• Refractive Index: 1.673
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.28±0.10(Predicted)
• CAS DataBase Reference: 6-(1H-Pyrazol-1-yl)nicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(1H-Pyrazol-1-yl)nicotinic acid(253315-22-9)
• EPA Substance Registry System: 6-(1H-Pyrazol-1-yl)nicotinic acid(253315-22-9)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 253315-22-9(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C9H7N3O2/c13-9(14)7-2-3-8(10-6-7)12-5-1-4-11-12/h1-6H,(H,13,14)

Upstream product

• 321533-62-4 6-(1H-pyrazol-1-yl)nicotinic acid methyl ester 
• 1428929-49-0 ethyl 6-(1H-pyrazol-1-yl)pyridine-3-carboxylate 
• 26218-78-0 methyl 6-bromonicotinate 

Downstream Products

• 321533-80-6 N,N-dimethyl-6-(1 H-pyrazol-1-yl)nicotinamide 

Relevant articles and documents

Arylamine compound, pharmaceutical composition containing arylamine compound as well as preparation method and application of arylamine compound

The present invention relates to an arylamine compound of a formula (I), a pharmaceutical composition comprising the same, a preparation method of the arylamine compound and application of the pharmaceutical composition in the prevention or treatment of diseases or conditions associated with RET activity.

Insight into structural requirements for selective and/or dual CXCR3 and CXCR4 allosteric modulators

Based on the previously published pyrazolopyridine-based hit compound for which negative allosteric modulation of both CXCR3 and CXCR4 receptors was disclosed, we designed, synthesized and biologically evaluated a set of novel, not only negative, but also positive allosteric modulators with preserved pyrazolopyridine core. Compound 9e is a dual negative modulator, inhibiting G protein activity of both receptors. For CXCR4 receptor para-substituted aromatic group of compounds distinguishes between negative and positive modulation. Para-methoxy substitution leads to functional antagonism, while para-chloro triggers agonism. Additionally, we discovered that chemotaxis is not completely correlated with G protein pathways. This is the first work in which we have on a series of compounds successfully demonstrated that it is possible to produce selective as well as dual-acting modulators of chemokine receptors, which is very promising for future research in the field of discovery of selective or dual modulators of chemokine receptors.

AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF

The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions cont

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I), and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophyla

AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF

The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions cont

Efficient N-arylation catalyzed by a copper(I) pyrazolyl-nicotinic acid system

Catalyst 6-(1H-pyrazol-1-yl)nicotinic acid L-CuCl behaves as a very active promoter of the N-arylation reactions, as it has been demonstrated with varieties of substrates under mild reaction conditions. A Cu(I) complex based on L of precatalyst has been isolated by a hydrothermal method and structurally characterized.

FUSED QUINOLINE DERIVATIVE AND USE THEREOF

The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein Rl is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6is (cyclic group optionally having substituent(s)) -carbonyl, and the like; R7, R8,R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7and R8,R8 and R9,and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and --- represents a single bond or a double bond, or a salt thereof, and the like.